JP2006523608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523608A5 JP2006523608A5 JP2004563063A JP2004563063A JP2006523608A5 JP 2006523608 A5 JP2006523608 A5 JP 2006523608A5 JP 2004563063 A JP2004563063 A JP 2004563063A JP 2004563063 A JP2004563063 A JP 2004563063A JP 2006523608 A5 JP2006523608 A5 JP 2006523608A5
- Authority
- JP
- Japan
- Prior art keywords
- asp
- cys
- tyr
- ser
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 241000024188 Andala Species 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
- 229960001220 amsacrine Drugs 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20026286A NO20026286D0 (no) | 2002-12-30 | 2002-12-30 | Nye peptider |
| PCT/NO2003/000444 WO2004058802A1 (en) | 2002-12-30 | 2003-12-29 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523608A JP2006523608A (ja) | 2006-10-19 |
| JP2006523608A5 true JP2006523608A5 (enExample) | 2007-02-22 |
Family
ID=19914347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563063A Pending JP2006523608A (ja) | 2002-12-30 | 2003-12-29 | Ｖｅｇｆ及びｖｅｇｆｒ−２のヘパリン結合ドメインに結合するペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060089307A1 (enExample) |
| EP (1) | EP1578785B1 (enExample) |
| JP (1) | JP2006523608A (enExample) |
| AT (1) | ATE386050T1 (enExample) |
| AU (1) | AU2003288810A1 (enExample) |
| DE (1) | DE60319135D1 (enExample) |
| NO (1) | NO20026286D0 (enExample) |
| WO (1) | WO2004058802A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
| EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| EP1812030A4 (en) * | 2004-10-14 | 2009-01-14 | Sopherion Therapeutics Inc | ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF |
| WO2006073314A1 (en) * | 2005-01-06 | 2006-07-13 | Ge Healthcare As | Optical imaging |
| EP2894161B1 (en) * | 2012-09-03 | 2019-12-25 | The University of Tokyo | Peptide for inhibiting vascular endothelial growth factor receptor |
| KR101531944B1 (ko) * | 2013-12-24 | 2015-06-29 | 광주과학기술원 | Ｖｅｇｆ에 특이적으로 결합하는 ｖｅｇｆ－ｂｐｂ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
| WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US5948667A (en) * | 1996-11-13 | 1999-09-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food | Xylanase obtained from an anaerobic fungus |
| TR200000547T2 (tr) * | 1997-08-27 | 2001-05-21 | Pioneer Hi-Bred International, Inc. | Lignin biyosentezi için enzimleri kodlayan genler ve bunların kullanımı. |
| WO1999014321A1 (en) * | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| EP1056773A2 (en) * | 1998-02-11 | 2000-12-06 | Resolution Pharmaceuticals Inc. | Angiogenesis targeting molecules |
| EP1248642A4 (en) * | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF |
| ES2293973T3 (es) * | 2000-02-03 | 2008-04-01 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos. |
| CA2327208A1 (en) * | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
| WO2003007689A2 (en) * | 2001-07-20 | 2003-01-30 | Eidgenoessische Technische Hochschule Zurich (Ethz) | Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| EP2014310B8 (en) * | 2002-03-01 | 2012-12-26 | Dyax Corp. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
-
2002
- 2002-12-30 NO NO20026286A patent/NO20026286D0/no unknown
-
2003
- 2003-12-29 AT AT03781116T patent/ATE386050T1/de not_active IP Right Cessation
- 2003-12-29 US US10/540,431 patent/US20060089307A1/en not_active Abandoned
- 2003-12-29 WO PCT/NO2003/000444 patent/WO2004058802A1/en not_active Ceased
- 2003-12-29 JP JP2004563063A patent/JP2006523608A/ja active Pending
- 2003-12-29 DE DE60319135T patent/DE60319135D1/de not_active Expired - Lifetime
- 2003-12-29 AU AU2003288810A patent/AU2003288810A1/en not_active Abandoned
- 2003-12-29 EP EP03781116A patent/EP1578785B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2452923A1 (en) | Peptide-based compounds for targeting integrin receptors | |
| JP2025122030A5 (enExample) | ||
| JP2006523608A5 (enExample) | ||
| CA2533321A1 (en) | Bicyclic peptide imaging agents | |
| JP2007535493A5 (enExample) | ||
| JP2025011099A5 (enExample) | ||
| CA2405469A1 (en) | Integrin binding peptide derivatives | |
| CA2726913A1 (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| JP2018505146A5 (enExample) | ||
| JP2005519041A5 (enExample) | ||
| CA2726917A1 (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
| JP2016501204A5 (enExample) | ||
| JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| JP2006524183A5 (enExample) | ||
| CA2121724A1 (en) | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | |
| TW202423949A (zh) | 一種靶向sstr2的化合物及其製備方法和應用 | |
| JPWO2021074622A5 (enExample) | ||
| AU2016222332A1 (en) | Quaternary assemblies of water-soluble helical foldamers, their use and production thereof | |
| TW202108603A (zh) | Ｍａｓｐ抑制性化合物及其用途 | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| TW201300133A (zh) | 以ｓｈｋ為主之醫藥組合物及其製備方法及用途 | |
| JPWO2020120983A5 (enExample) | ||
| JPWO2020148527A5 (enExample) | ||
| JP2017500849A5 (enExample) | ||
| JP2003528814A5 (enExample) |